Trial reportEuropean journal of neurology2026
Long-Term Improvements Following Initial Migraine Response in Eptinezumab-Treated Participants With Migraine for Whom 2-4 Prior Preventive Treatments Have Failed.
Trial report in European journal of neurology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04418765 (Interventional, Randomized, Double-blind, Parallel-group, Placebo-controlled Study With an Extension Period to Evaluate the Efficacy and Safety of Eptinezumab for the Prevention of Migraine in Patients With Unsuccessful Prior Preventive Treatments), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Interventional, Randomized, Double-blind, Parallel-group, Placebo-controlled Study With an Extension Period to Evaluate the Efficacy and Safety of Eptinezumab for the Prevention of Migraine in Patients With Unsuccessful Prior Preventive Treatments
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundIn the DELIVER trial, eptinezumab administration was associated with sustained reductions in headache frequency and migraine-related impact in participants for whom previous preventive treatments have failed. This post hoc analysis evaluated long-term maintenance of initial ≥ 50% and ≥ 75% migraine response.
methodsDELIVER was a 24-week, randomized, double-blind, placebo-controlled trial with a 48-week dose-blinded extension. For participants with initial ≥ 50% or ≥ 75% reduction in monthly migraine days-defined as response following their first dose (Weeks 1-12) or first and second dose (Weeks 1-24)-maintenance of ≥ 50% or ≥ 75% migraine response was assessed for each subsequent 12-week dosing interval. Proportions of severe migraine attacks, 6-Item Headache Impact Test (HIT-6) total score, migraine-specific Work Productivity and Activity Impairment (WPAI:M) presenteeism subscore, and Patient Global Impression of Change (PGIC) categories were also evaluated in Weeks 1-12 responders.
resultsOf participants with ≥ 50% migraine response over Weeks 1-12, 61.0% (69/113, 100 mg) and 73.8% (93/126, 300 mg) maintained response over the entire 72-week treatment period; ≥ 50% responders (Weeks 1-24) and ≥ 75% responders (Weeks 1-12 and 1-24) showed similar trends. Weeks 1-12 responders (≥ 50% and ≥ 75%) experienced sustained reductions in migraine severity, HIT-6 total score, and presenteeism subscore, with most reporting improvements per the PGIC.
conclusionsFor both eptinezumab doses, ≥ 50% or ≥ 75% migraine response over Weeks 1-12 or 1-24 was maintained for the entire 72-week treatment period for many participants. An initial response within the first two doses of eptinezumab can indicate long-term improvements.
trial registrationClinicalTrials.gov (Identifier: NCT04418765; URL: https://clinicaltrials.gov/study/NCT04418765); EudraCT (Identifier: 2019-004497-25; URL: https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004497-25).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.